Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study

Clinical Therapeutics

Volumn 32, Issue 7, 2010, Pages 1252-1269

  Oparil, Suzanne ^a   Melino, Michael ^b   Lee, James ^b   Fernandez, Victor ^b   Heyrman, Reinilde ^b  

^a University of Alabama at Birmingham   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Amlodipine besylate; Antihypertensive therapy; Blood pressure; Fixed dose combination therapy; Olmesartan medoxomil

Indexed keywords

AMLODIPINE BESYLATE; AMLODIPINE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TETRAZOLES;

EID: 77955251021     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.07.008     Document Type: Article

References (33)

1. High blood pressure-statistics American Heart Association, Accessed January 6, 2010. http://www.americanheart.org/downloadable/heart/1261003279882FS14HBP10.pdf.
2. Egan BM, Zhao Y, Axon RN US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010, 303:2043-2050.
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA. 2003, 289:2560-2572. National Heart, Lung, Blood Institute Joint National Committee on Prevention, Detection, EvaluationBlood Institute Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood PressureTreatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating CommitteeNational High Blood Pressure Education Program Coordinating Committee.
4. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004, 363:2022-2031. VALUE Trial Group.
5. Nasser SA, Lai Z, O'Connor S, et al. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events?. Curr Hypertens Rep. 2008, 10:398-404.
6. Staessen JA, Thijisq L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004, 22:847-857. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
7. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004, 363:2049-2051.
8. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002, 4:393-404. ALLHAT Collaborative Research Group.
9. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Out- comes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005, 366:895-906. ASCOT Investigators.
10. Jackson KC, Sheng X, Nelson RE, et al. Adherence with multiplecombination antihypertensive pharmacotherapies in a US managed care database. Clin Ther. 2008, 30:1558-1563.
11. Brixner DI, Jackson KC, Sheng X, et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free- and fixed-dose combinations. Curr Med Res Opin. 2008, 24:2597-2607.
12. Neutel JM The role of combination therapy in the management of hypertension. Nephrol Dial Transplant. 2006, 21:1469-1473.
13. Elijovich F, Laffer C A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis. 2009, 3:231-240.
14. Ethical principles for medical research involving human subjects World Medical Association Declaration of Helsinki, Accessed May 20, 2010. http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
15. McDonald JH Handbook of Biological Statistics 2009, Sparky House Publishing, Baltimore, Md. 2nd ed.
16. Chrysant SG, Weber MA, Wang AC, Hinman DJ Evaluation of antihy-pertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004, 17:252-259.
17. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, doubleblind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008, 30:587-604.
18. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of longterm treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich). 2009, 11:475-482.
19. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006, 47:345-351.
20. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967, 202:1028-1034.
21. Chapman N, Chang CL, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008, 118:42-48. ASCOT Investigators.
22. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002, 359:995-1003. LIFE Study Group.
23. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with neph-ropathy due to type 2 diabetes. N Engl J Med. 2001, 345:851-860. Collaborative Study Group.
24. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: A cluster randomized, controlled trial. Hypertension. 2009, 53:646-653.
25. Rose AJ, Shimada SL, Rothendler JA, et al. The accuracy of clinician perceptions of "usual" blood pressure control. J Gen Intern Med. 2008, 23:180-183.
26. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001, 135:825-834.
27. Black HR Triple fixed-dose combination therapy: Back to the past. Hypertension. 2009, 54:19-22.
28. Wald DS, Law M, Morris JK, et al. Combination therapy versus mono-therapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009, 122:290-300.
29. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009, 120:1598-1605.
30. Law MR, Morris JK, Wald NJ Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009, 338:b1665.
31. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008, 51:1403-1419.
32. Brown MA, Buddle ML, Martin A Is resistant hypertension really resistant?. Am J Hypertens. 2001, 14:1263-1269.
33. Hermida RC, Ayala DE, Calvo C, et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension. 2005, 46:1053-1059.